Did You Know?

Effective March 31, 2021, the Colorado Department of Health Care Policy & Financing (the Department’s) website will have a new look. The web address will remain the same, so any bookmarked pages should not be affected. This does not affect the Provider Web Portal.

Durable Medical Equipment, Prosthetics, Orthotics and Supplies (DMEPOS) Providers

Span Billing for Certain Supplies

The following items may have a date span of up to 30 calendar days on claims:

- Diabetic testing supplies (i.e., test strips, lancets)
- Continuous passive motion (CPM) devices
- Parenteral and enteral nutrition
- Parenteral and enteral administration kits
- External infusion pump supplies

Suppliers must enter the “from” and “to” dates of service on any claim for the items listed above. The “from” date is when the items were provided to the member. The “to” date is the last date the supplies are expected to be used. For example, if providing a 30-day supply of diabetic testing strips to a member, the “from” date on the claim would be “01/01/2021” and the “to” date would be “01/30/2021”.

Contact Alex Weichselbaum at Alex.Weichselbaum@state.co.us with any questions.

Improving health care access and outcomes for the people we serve while demonstrating sound stewardship of financial resources.
Federally Qualified Health Centers (FQHCs)

Encounter Rate “Carve-Out” – COVID-19 Vaccine and Monoclonal Antibody Therapy Treatments

Effective February 12, 2021, Rule10 CCR 2505-10 8.700 was updated so that FQHCs can be reimbursed at the fee schedule rates for administering the COVID-19 vaccines and monoclonal antibody treatments. FQHCs must submit a professional claim (CMS1500/837p) to receive reimbursement for these services at the Fee Schedule rates below.

FQHCs are significant to Colorado, providing services to underserved areas and populations. Expanding reimbursement for COVID-19 vaccine administration and COVID-19 monoclonal antibody therapy treatments will help FQHCs battle the COVID-19 pandemic. Current reimbursement rates are listed below. Refer to the latest Fee Schedule for future rate updates on the Provider Rates & Fee Schedule web page.

COVID-19 Vaccine Administration Methods Fee-for-Service Billing:

<table>
<thead>
<tr>
<th>Code</th>
<th>CPT Short Descriptor</th>
<th>Labeler Name</th>
<th>Vaccine/Procedure Name</th>
<th>Effective March 15, 2021, Fee-For-Service Rates</th>
</tr>
</thead>
<tbody>
<tr>
<td>0001A</td>
<td>ADM SARSCOV2 30MCG/0.3ML 1ST</td>
<td>Pfizer</td>
<td>Pfizer-Biontech Covid-19 Vaccine Administration - First Dose</td>
<td>$41.18</td>
</tr>
<tr>
<td>0002A</td>
<td>ADM SARSCOV2 30MCG/0.3ML 2ND</td>
<td>Pfizer</td>
<td>Pfizer-Biontech Covid-19 Vaccine Administration - Second Dose</td>
<td>$41.18</td>
</tr>
<tr>
<td>0011A</td>
<td>ADM SARSCOV2 100MCG/0.5ML1ST</td>
<td>Moderna</td>
<td>Moderna Covid-19 Vaccine Administration - First Dose</td>
<td>$41.18</td>
</tr>
<tr>
<td>0012A</td>
<td>ADM SARSCOV2 100MCG/0.5ML2ND</td>
<td>Moderna</td>
<td>Moderna Covid-19 Vaccine Administration - Second Dose</td>
<td>$41.18</td>
</tr>
<tr>
<td>0031A</td>
<td>ADM SARSCOV2 VAC AD26 .5ML</td>
<td>Janssen</td>
<td>Janssen Covid-19 Vaccine Administration</td>
<td>$41.18</td>
</tr>
</tbody>
</table>
COVID-19 Monoclonal Antibody Therapy Treatment Administration Methods Fee-for-Service Billing:

<table>
<thead>
<tr>
<th>Code</th>
<th>CPT Short Descriptor</th>
<th>Labeler Name</th>
<th>Vaccine/Procedure Name</th>
<th>Effective Fee-For-Service Rates</th>
</tr>
</thead>
<tbody>
<tr>
<td>M0239</td>
<td>bamlanivimab-xxxx infusion</td>
<td>Eli Lilly</td>
<td>Intravenous infusion, bamlanivimab-xxxx, includes infusion and post administration monitoring</td>
<td>$309.60</td>
</tr>
<tr>
<td>M0243</td>
<td>casirivi and imdevi infusion</td>
<td>Regeneron</td>
<td>Intravenous infusion, casirivimab and imdevimab includes infusion and post administration monitoring</td>
<td>$309.60</td>
</tr>
<tr>
<td>M0245</td>
<td>bamlan and etesev infusion</td>
<td>Eli Lilly</td>
<td>Intravenous infusion, bamlanivimab and etesevimab, includes infusion and post administration monitoring</td>
<td>$309.60</td>
</tr>
</tbody>
</table>

Since it is anticipated that providers will not initially incur a cost for the product, the payment allowance will be updated for the product at a later date.

Note: If the COVID-19 vaccine or monoclonal antibody therapy treatments are provided as part of a regular billable visit, FQHCs can receive their encounter rate reimbursement in addition to the fee schedule reimbursement. Two separate claims may be submitted in these circumstances (one institutional claim for the encounter reimbursement, one professional claim for the fee schedule reimbursement).

The rules were updated under 8.700 of the Department Program Rules and Regulations.

Contact Morgan Anderson at Morgan.Anderson@state.co.us or Erin Johnson at Erink.Johnson@state.co.us with any questions.
COVID-19 Monoclonal Antibody Infusions

On February 9, 2021, the U.S. Food and Drug Administration (FDA) issued an Emergency Use Authorization (EUA) for the monoclonal antibody COVID-19 therapy bamlanivimab and etesevimab, administered together.

When bamlanivimab and etesevimab doses are provided without charge from the Federal government and administered together, providers should only submit claims to Health First Colorado (Colorado’s Medicaid Program) for the administration procedure codes and should not include the monoclonal antibody specific procedure codes on the claim. If codes are billed for the monoclonal antibodies, the line(s) may pay at zero or be denied. This information is subject to change dependent on the COVID-19 public health emergency declaration.

The following table should be used as a procedure code reference for the duration of the declaration.

<table>
<thead>
<tr>
<th>Procedure Code</th>
<th>Long Description</th>
<th>Short Description</th>
<th>EUA Effective Date</th>
</tr>
</thead>
<tbody>
<tr>
<td>Q0239</td>
<td>Injection, bamlanivimab-xxxx, 700 mg</td>
<td>bamlanivimab-xxxx</td>
<td>11/9/2020</td>
</tr>
<tr>
<td>M0239</td>
<td>Intravenous infusion, bamlanivimab-xxxx, includes infusion and post administration monitoring</td>
<td>bamlanivimab-xxxx infusion</td>
<td>11/9/2020</td>
</tr>
<tr>
<td>Q0243</td>
<td>Injection, casirivimab and imdevimab, 2400 mg</td>
<td>casirivimab and imdevimab</td>
<td>11/21/2020</td>
</tr>
<tr>
<td>M0243</td>
<td>Intravenous infusion, casirivimab and imdevimab includes infusion and post administration monitoring</td>
<td>casirivi and imdevi infusion</td>
<td>11/21/2020</td>
</tr>
<tr>
<td>Q0245</td>
<td>Injection, bamlanivimab and etesevimab, 2100 mg</td>
<td>bamlanivimab and etesevima</td>
<td>2/9/2021</td>
</tr>
<tr>
<td>M0245</td>
<td>Intravenous infusion, bamlanivimab and etesevimab, includes infusion and post administration monitoring</td>
<td>bamlan and etesev infusion</td>
<td>2/9/2021</td>
</tr>
</tbody>
</table>
Providers may refer to resources below for additional information:

- Lilly Neutralizing Antibodies for COVID-19
- Fact Sheet for Health Care Providers Emergency Use Authorization (EUA) of Bamlanivimab
- Fact Sheet for Health Care Providers Emergency Use Authorization (EUA) of Bamlanivimab and Etesevimab
- Regeneron Casirivimab and Imdevimab EUA Guidebook
- Fact Sheet for Health Care Providers Emergency Use Authorization (EUA) of Casirivimab and Imdevimab

Contact HCPF_PAD@state.co.us with questions or concerns.

---

**Fee-for-Service Prior Authorization Requests (PARs) and Physician Administered Drugs (PAD) Providers**

**New Utilization Management (UM) Vendor Update**

Keystone Peer Review Organization (Kepro) will be the new UM partner for Health First Colorado as previously announced in the [February 2021 Provider Bulletin (B2100459)](https://example.com) and [March 2021 Provider Bulletin (B2100460)](https://example.com).

Any information regarding the UM vendor transition from eQHealth Solutions Inc. to Kepro does not pertain to:

1) Providers who submit PARs through Single Entry Point (SEP) or Community Centered Board (CCB) Agencies (for example Adult Long-Term Home Health)

2) Providers who submit reviews for waivers under Office of Community Living (OCL) waivers, including Over Cost Containment (OCC), Children's Extensive Services (CES), Preadmission Screening and Resident Review (PASRR) and Children’s Home & Community-Based Services (CHCBS). These reviews were transitioned to the Department’s vendor as of March 1, 2021. Visit the [Long-Term Services and Supports Training web page](https://example.com) and scroll down to the section titled Telligen's Qualitrac Review and Provider Portal for more information about that transition.

Kepro will begin accepting PARs for select outpatient services as of May 1, 2021. Kepro will be responsible for the prior authorization of codes that require a PAR per the [Health First Colorado Fee Schedule](https://example.com) and also fall within the following benefit areas: Audiology, Durable Medical Equipment, Medical Procedures, Diagnostic Imaging, Molecular Testing, Pediatric Behavioral Therapy, Early and Periodic Screening, Diagnostic, and Treatment (EPSDT) Exceptions, Outpatient Speech, Occupational and Physical Therapy, Out-of-State Inpatient Hospital
Requests, Personal Care and Transplants. Visit the [ColoradoPAR Program web page](https://www.coloradopar.com) to register for training and to read about the training curriculum.

At a later date, Kepro will be prior authorizing Pediatric Long-Term Home Health, Private Duty Nursing and select Physician Administered Drugs, as well as the Inpatient Hospital Review Program. Additional information about those implementation dates will be forthcoming on the [ColoradoPAR program web page](https://www.coloradopar.com) and via Provider Bulletin.

**Physician Administered Drugs (PADs)**

A select group of PADs that will require prior authorization will be implemented with KEPRO. Information pertaining to PAD PARs will be posted on the [Physician Administered Drugs web page](https://www.coloradopar.com/physician-administered-drugs). The go-live date for KEPRO and prior authorization of PADs will begin no earlier than June 1, 2021. Additional announcements will be posted to the [Physician Administered Drugs web page](https://www.coloradopar.com/physician-administered-drugs), [ColoradoPAR: Health First Colorado Prior Authorization Request Program web page](https://www.coloradopar.com), and sent out via Provider Bulletin.

---

**Hospital Providers**

**General Updates**

**All Hospital Providers**

**Hospital Stakeholder Engagement Meetings**

Bi-monthly Hospital Engagement meetings will continue to be hosted to discuss current issues regarding payment reform and operational processing. [Sign up to receive the Hospital Stakeholder Engagement Meeting newsletters.](https://www.coloradopar.com)

- The next Rural Hospital Engagement meeting is scheduled for **Thursday, May 6, 2021, from 2:00 p.m. - 4:00 p.m. MT** and will be hosted virtually.
- The All-Hospital Engagement meeting is scheduled for **Friday, May 7, 2021, from 9:00 a.m. - 12:00 p.m. MT** and will be hosted virtually.

Visit the [Hospital Engagement Meeting web page](https://www.coloradopar.com) for more details, meeting schedules and past meeting materials. **Calendar Year 2021 meetings have been posted.**

Contact Andrew Abalos at [Andrew.Abalos@state.co.us](mailto:Andrew.Abalos@state.co.us) with any questions or topics to be discussed at future meetings. Advanced notice will provide the Rates team time to bring additional Department personnel to the meetings to address different concerns.

**Rural Health Clinics**

Bi-monthly Rural Health Clinic Engagement meetings will continue to be hosted to discuss current issues regarding payment reform and operational processing.
The next Rural Health Clinic Engagement meeting is scheduled for Thursday, May 6, 2021, from 12:30 p.m. to 1:30 p.m. MT and will be hosted virtually. The meetings are now held on Zoom.

Visit the Rural Health Clinic Engagement Meeting web page for more details, meeting schedules and past meeting materials. Calendar Year 2021 meetings have been posted.

Contact Erin Johnson at Erin.Johnson@state.co.us with any questions or topics to be discussed at future meetings. Advanced notice will provide the Rates team time to bring additional Department personnel to the meetings to address different concerns.

Hospital Transformation Program (HTP) Update

Hospital HTP Application and Portal Training

On March 4, 2021, a training session was hosted for HTP participating hospitals to go over the HTP hospital application process and an orientation of the submission portal. As a reminder, per a special communication from Executive Director Kim Bimestefer in November 2020, the HTP implementation date was moved to April 1, 2021. The training is posted on the Colorado Hospital Transformation Program web page.

Updates from the Office of eHealth Innovation (OeHI)

This week, several updates came from OeHI of interest to hospitals and stakeholders.

New Care Coordination Resources

As part of Colorado’s Health IT Roadmap Care Coordination Initiative, OeHI and the eHealth Commission developed new resources to increase collaboration, alignment and coordination of efforts. See below and please share with your networks.

The Social-Health Information Exchange (S-HIE) white paper titled Advancing a Coordinated Ecosystem for a Social Health Information Exchange (S-HIE) aims to create a shared vision among Colorado stakeholders interested in improving whole-person care coordination.

The Social Determinants of Health (SDoH) Screening Guide titled Implementation Guidance For Screening for Social Determinants of Health in an Electronic Health Record aims to support health care providers (such as community health centers, independent practices, health systems and community mental health centers) interested in screening for SDoH and documenting the results in an electronic health record.

Both resources are available on OeHI’s Care Coordination web page.

State’s Prescriber Tool- Licenses Available

As part of Colorado’s Health IT Roadmap efforts to support the Polis-Primavera Administration’s bold priorities to improve access to affordable and high quality health care, the Department is providing a limited number of FREE licenses to the state’s prescriber tool
to eligible Medicaid providers. This is phase one of several phases that leverage foundational health IT infrastructure, policies and innovations. Complete the [HCPF Open License Access (HOLA) Program form](#) to request a license.

**Colorado Healthcare Affordability and Sustainability Enterprise (CHASE) Board Meeting**

The next CHASE Board meeting will take place via webinar on Tuesday, April 27, 2021, at 3:00 p.m. MT. Additional information about the board, as well as meeting materials, can be found on the [Colorado Healthcare Affordability and Sustainability Enterprise (CHASE) Board web page](#).

---

**Hospitals, Federally Qualified Health Centers (FQHCs), Physician Administered Drugs (PADs), Physicians, Pharmacy Providers**

### Increases in Medicaid Reimbursement for All COVID-19 Vaccine Administration

Effective March 15, 2021, all COVID-19 vaccine claims will be reimbursed at $41.18 in accordance with updated guidance and funding from the Centers for Medicare & Medicaid Services (CMS). This applies to physicians, federally qualified health centers (FQHC), hospitals, pharmacies and other Health First Colorado-enrolled qualified immunizers administering each dose of a COVID-19 vaccine approved by the U.S. Food and Drug Administration (FDA) under their Emergency Use Authorization (EUA) authority.

Pharmacists enrolled with Health First Colorado may submit claims for reimbursement of the administration of COVID-19 vaccines to Health First Colorado members. Providers will receive vaccine products from the federal government at no cost. Only the administration fee associated with the vaccines may be reimbursed to providers. These updated rates can be found on the Department’s Provider Rates and Fees website under the [Immunization Rate Schedule](#) section. Additional information for providers can be found on the [COVID-19 Information for Health First Colorado and CHP+ Providers and Case Managers web page](#). Providers will need to [enroll in the State’s vaccine program](#) to offer the vaccine.

**COVID-19 Vaccine Administration Methods Fee-for-Service Billing:**

<table>
<thead>
<tr>
<th>Code</th>
<th>CPT Short Descriptor</th>
<th>Labeler Name</th>
<th>Vaccine/Procedure Name</th>
<th>Effective January 1, 2021, Fee-For-Service Rates</th>
</tr>
</thead>
<tbody>
<tr>
<td>0001A</td>
<td>ADM SARSCOV2 30MCG/0.3ML 1ST</td>
<td>Pfizer</td>
<td>Pfizer-Biontech Covid-19 Vaccine Administration - First Dose</td>
<td>$41.18</td>
</tr>
<tr>
<td>Code</td>
<td>CPT Short Descriptor</td>
<td>Labeler Name</td>
<td>Vaccine/Procedure Name</td>
<td>Effective January 1, 2021, Fee-For-Service Rates</td>
</tr>
<tr>
<td>--------</td>
<td>--------------------------------</td>
<td>--------------</td>
<td>---------------------------------------------</td>
<td>--------------------------------------------------</td>
</tr>
<tr>
<td>0002A</td>
<td>ADM SARS-CoV2 30MCG/0.3ML 2ND</td>
<td>Pfizer</td>
<td>Pfizer-Biontech Covid-19 Vaccine Administration - Second Dose</td>
<td>$41.18</td>
</tr>
<tr>
<td>0011A</td>
<td>ADM SARS-CoV2 100MCG/0.5ML1ST</td>
<td>Moderna</td>
<td>Moderna Covid-19 Vaccine Administration - First Dose</td>
<td>$41.18</td>
</tr>
<tr>
<td>0012A</td>
<td>ADM SARS-CoV2 100MCG/0.5ML2ND</td>
<td>Moderna</td>
<td>Moderna Covid-19 Vaccine Administration - Second Dose</td>
<td>$41.18</td>
</tr>
</tbody>
</table>

**Johnson & Johnson Single-dose Vaccine Administration**

Effective February 26, 2021, the Department is covering the administration of the Janssen (Johnson & Johnson) single-dose COVID-19 vaccine.

Claims may be reimbursed for enrolled and qualified providers for administration of COVID-19 vaccines approved by the U.S. Food and Drug Administration (FDA) under their Emergency Use Authorization (EUA) authority. Pharmacists enrolled with Health First Colorado may submit claims for reimbursement of the administration of COVID-19 vaccines to Health First Colorado members. Providers will receive vaccine products from the federal government at no cost. Only the administration fee associated with the vaccines may be reimbursed to providers.

**COVID-19 Vaccine Administration Method Fee-for-Service Billing - Janssen (Johnson & Johnson) Single-Dose Vaccine:**

<table>
<thead>
<tr>
<th>Code</th>
<th>CPT Short Descriptor</th>
<th>Labeler Name</th>
<th>Vaccine/Procedure Name</th>
<th>Effective February 26, 2021, Fee-For-Service Rates</th>
</tr>
</thead>
<tbody>
<tr>
<td>0031A</td>
<td>ADM SARS-CoV2 VAC AD26 .5ML</td>
<td>Janssen (Johnson &amp; Johnson)</td>
<td>Janssen Covid-19 Vaccine Administration</td>
<td>$41.18</td>
</tr>
</tbody>
</table>

Contact Matthew Colussi at Matthew.Colussi@state.co.us with any questions.
Pharmacies and All Medication-Prescribing Providers

Brand Name Medication Favored Over Equivalent Generic

Certain brand name products are managed by favoring them over the generic equivalent non-preferred medications. The list of brand favored over generic products has migrated off of Appendix P and is now posted in a separate document titled, “Brand Favored Product List” which may be accessed from the Pharmacy Resources web page. The Brand Favored Product List is a list of all pharmacy benefit brand favored drugs including those on the Preferred Drug List (PDL), those not on the PDL, and those on Appendix P.

If a generic is medically necessary for the member (over the equivalent brand name), additional clinical information will need to be provided during the normal prior authorization process.

Pharmacies may reach out to Rx Management Pharmacy Call Center at 1-800-424-5725 for assistance, 24 hours a day, 7 days a week.

Providers are reminded that Brand Suboxone Film is favored over generic buprenorphine-naloxone film. Please see the Appendix P, BUPRENORPHINE CONTAINING PRODUCTS section, for more details.

Bydureon Discontinuation and Trulicity Preferred

Effective April 1, 2021, Trulicity (dulaglutide) Pen Injector will be preferred by Health First Colorado, in addition to the currently preferred products listed on the Preferred Drug List (PDL). Manufacturing of Bydureon Pen has been discontinued by the manufacturer.

All preferred Glucagon-like Peptide-1 Receptor Agonists (GLP-1 Analogues) require a 3-month trial of (or documented contraindication to) metformin therapy prior to approval.

Additional prior authorization criteria for all preferred and non-preferred medications can be found on the Preferred Drug List. Call the Rx Management Pharmacy Call Center at 1-800-424-5725 with questions regarding rejected claims or prior authorization.
Pharmacy and Therapeutics (P&T) Committee Meeting

Tuesday, April 13, 2021
1:00 p.m. - 5:00 p.m. MT
Meeting to be held virtually.
Visit the Pharmacy and Therapeutics (P&T) Committee web page for the agenda and meeting information.

Pharmacy and Therapeutics (P&T) Committee Member Openings

The Department has two open positions for the P&T Committee member terms 2021-2022.
Applicants are being accepted for the following open positions:

- One physician who specializes in the practice of psychiatry
- One physician who specializes in the treatment of members with disabilities

If interested in serving or know someone who would be qualified, please submit/have them submit a CV along with a completed Conflict of Interest form to:

Colorado Department of Health Care Policy and Financing
Attn: Brittany Schock, PharmD
Fax to 303-866-3590 or email Brittany.Schock@state.co.us

Preferred Drug List (PDL) Announcement of Preferred Products

The following PDL drug classes and preferred agents are effective April 1, 2021.

Alpha Blockers
Preferred products will be: Prazosin capsule

Beta-Blockers & Combinations
Preferred products will be: Acebutolol, Atenolol, Atenolol/Chlorthalidone, Bisoprolol, Bisoprolol/HCTZ, Bystolic, Carvedilol IR/ER, Labetalol, Metoprolol, Metoprolol XL, Metoprolol/HCTZ, Nadolol, Pindolol, Propranolol IR tablet/solution, Propranolol ER, Sotalol

Calcium Channel Blockers (CCBs)
Preferred products will be: Amlodipine, Diltiazem IR tablet, Diltiazem ER capsule, Felodipine ER, Nifedipine IR/ER, Verapamil IR/ER tablet, Verapamil ER 120 mg, 180 mg, 240 mg capsule
Lipotropics, Bile Acid Sequestrants
Preferred products will be: Cholestyramine/Aspartame, Cholestyramine/Sucrose, Colesevelam tablet, Colestipol tablet

Lipotropics, Other
Preferred products will be: Ezetimibe, Fenofibrate tablet/capsule (generic Lofibra/Tricor), Gemfibrozil, Niacin ER, Omega-3 ethyl esters (generic Lovaza)

Statins/Statin Combinations
Preferred products will be: Atorvastatin, Lovastatin, Pravastatin, Rosuvastatin, Simvastatin

Anti-Parkinson's Agents
Preferred products will be: Amantadine, Benztropine, Carbidopa/Levodopa IR, Carbidopa/Levodopa ER, Carbidopa/Levodopa/Entacapone, Pramipexole IR, Ropinirole IR, Selegiline, Trihexyphenidyl tablet/elixir

Atypical Antipsychotics
Preferred products will be: Aripiprazole tablet, Clozapine tablet, Latuda (2nd Line), Olanzapine, Quetiapine IR/ER, Risperidone, Ziprasidone

CGRP Inhibitors
Preferred products will be: Emgality 120mg syringe, Emgality pen, Aimovig auto-injector

Lithium Agents
Preferred products will be: Lithium carbonate tablet/capsule, Lithium ER tablet

Neurocognitive Disorder Agents
Preferred products will be: Donepezil 5mg/10mg tablet, Donepezil ODT, Memantine tablet, Rivastigmine capsule/patch

Sedative Hypnotics- Non-Benzodiazepines
Preferred products will be: Eszopiclone, Zaleplon, Zolpidem IR/ER

Sedative Hypnotics- Benzodiazepines
Preferred products will be: Temazepam 15mg, Temazepam 30mg, Triazolam

Anxiolytics - Benzodiazepines
Preferred products will be: Alprazolam IR tablet, Alprazolam ER tablet, Chlordiazepoxide, Clorazepate, Diazepam tablet, Diazepam solution, Lorazepam tablet/solution, Oxazepam

Anxiolytics - Non-Benzodiazepines
Preferred products will be: Buspirone
Topical Steroids (Low Potency)
Preferred products will be: Derma-Smoothe (BNR) oil, Desonide 0.05% cream/ointment, Fluocinolone 0.01% cream, Hydrocortisone (Rx) cream/lotion/ointment

Topical Steroids (Medium Potency)
Preferred products will be: Betamethasone dipropionate lotion, Betamethasone valerate ointment, Fluocinolone 0.025% cream, Fluticasone cream/ointment, Mometasone cream/ointment/solution, Triamcinolone 0.025%, 0.1% cream/lotion/ointment

Topical Steroids (High Potency)
Preferred products will be: Betamethasone Dipropionate/Propylene Glycol (aug.) cream, Fluocinonide 0.05% gel/ointment/solution, Triamcinolone 0.5% cream/ointment

Topical Steroids (Very High Potency)
Preferred products will be: Betamethasone Dipropionate/Propylene Glycol (aug.) ointment, Clobetasol Propionate cream/gel/ointment/solution, Fluocinonide 0.1% cream

Insulins (Mixtures)
Preferred products will be: Humalog Mix 50/50 pen/vial, Humalog Mix 75/25 pen/vial, Humulin 70/30 vial/pen (OTC), Novolog Mix 70/30 vial/pen

Insulins (Long-acting)
Preferred products will be: Lantus pen/vial, Levemir pen/vial

Insulins (Intermediate-acting)
Preferred products will be: Humulin N vial (OTC), Novolin N pen/vial (OTC)

Insulins (Rapid-acting)
Preferred products will be: Humalog cartridge/pen/vial, Humalog Jr. pen, Novolog cartridge/pen/vial

Insulins (Short-acting)
Preferred products will be: Humulin R vial (OTC), Humulin R U-500 vial/pen, Novolin R pen/vial (OTC)

Glucagon, Self-Administered
Preferred products will be: GlucaGen hypokit, Glucagon emergency kit, Gvoke pen/syringe

Growth Hormones
Preferred products will be: Genotropin, Norditropin

Bile Salts
Preferred products will be: Ursodiol capsule/tablet
Hemorrhoidal, Anorectal and Topical Anesthetic Agents

Preferred products will be: Anusol HC 2.5% cream, Cortifoam 10% aerosol, Hydrocortisone 1% (Rx) cream/kit, Hydrocortisone 2.5% cream/kit, Hydrocortisone enema, Hydrocortisone/Lidocaine 3-0.5% cream, Lidocaine 5% ointment, Lidocaine/Prilocaine 2.5%-2.5% cream, Proctofoam 1%-1% foam, Proctosol HC 2.5% cream, Proctozone HC 2.5% cream

Immune Globulins

Preferred products will be: Cuvitru, Gammagard liquid, Gammaked, Gammaplex, Gamunex-C, Hizentra, Privigen

Intranasal Rhinitis Agents

Preferred products will be: Azelastine, Budesonide (OTC), Fluticasone (Rx), Ipratropium, Triamcinolone (OTC)

Leukotriene Modifiers

Preferred products will be: Montelukast chewable/tablet

Multiple Sclerosis Agents

Preferred products will be: Aubagio, Avonex, Betaseron, Copaxone 20mg (BNR), Gilenya, Tecfidera (BNR )

Ophthalmic Allergy Agents

Preferred products will be: Alrex, Cromolyn, Ketotifen (OTC), Lastacaft, Olopatadine (RX), Pazeo (Rx)

Ophthalmic Anti-inflammatory Agents

Preferred products will be: Diclofenac, Flarex, Flurbiprofen, Fluorometholone, FML Forte, Ilevro, Ketorolac, Lotemax drops (BNR)/ointment, Maxidex, Pred Mild, Prednisolone acetate

Ophthalmic Glaucoma Agents

Preferred products will be: Alphagan P 0.15% (BNR), Alphagan P 0.1%, Azopt, Brimonidine 0.2%, Combigan, Dorzolamide, Dorzolamide/Timolol, Dorzolamide/Timolol PF, Latanoprost, Levobunolol, Lumigan (BNR), Timolol (generic Timoptic), Travatan Z (BNR)

Pharmacy Providers

Reminder to Update Fax Numbers

Pharmacy providers are encouraged to ensure their fax numbers are accurate and current to receive important pharmacy fax blasts. Many pharmacies either do not have a fax number on file or have a corporate fax number on record.

Visit the Provider Maintenance - Provider Web Portal Quick Guide web page for more information on updating the fax number.
Value Based Contracting
The Health First Colorado pharmacy team is seeking opportunities to partner with pharmaceutical manufacturers through Value Based Contracting arrangements. The Department is encouraging manufacturers that are interested in collaborating in a mutually beneficial manner to email hcpf_Colorado.SMAC@state.co.us. The following information is requested in the email:

- Manufacturer name / Representative name
- Drug(s) for Value Based Contracting
- Population involved
- Intervention
- Baseline
- Outcome
- Time horizon

Once the request is received, providers will be outreached to set up a telephone appointment. The Department will meet with interested groups through April 15, 2021, to establish phase one of the program.

Physician-Administered Drug (PAD) Providers
Quarter 2 Rate Updates 2021
The PAD rates for the second quarter of 2021 have been updated. The new rates are effective April 1, 2021, and are posted to the Provider Rates & Fee Schedule web page under the Physician Administered Drug Fee Schedule drop-down section.

Contact Marli Firillo at Marli.Firillo@state.co.us and Tyler Collinson at Tyler.Collinson@state.co.us with any questions about PAD rates.

Telemedicine Providers
Telemedicine Report Available
The Telemedicine Evaluation Report is now available on the Telemedicine & eConsults Policy Development web page. This report summarizes the research and work completed by the Department from June 2020 through December 2020. It contains an evaluation of the policy changes in telemedicine since the beginning of the pandemic. It also details what is known thus far about the impacts on access to care and utilization, health equity, quality and member outcomes, and payment and reimbursement.
Fee-for-service telemedicine utilization data is posted on a bi-monthly basis and can be found on the Telemedicine - Provider Information web page.

Contact Policy Development and Stakeholder Relations Specialist Betsy J. Holt, MSS, at Betsy.Holt@state.co.us for more information.

Provider Billing Training Sessions

April and May 2021 Provider Billing Webinar-Only Training Sessions

Providers are invited to participate in training sessions for an overview of Health First Colorado billing instructions and procedures. The current and following months' workshop calendars are shown below.

Who Should Attend?

Staff who submit claims, are new to billing Health First Colorado services, or need a billing refresher course should consider attending one or more of the following provider training sessions.

The institutional claims (UB-04) and professional claims (CMS 1500) training sessions provide high-level overviews of claim submission, prior authorizations, navigating the Department’s website, using the Provider Web Portal, and more. For a preview of the training materials used in these sessions, refer to the Beginner Billing Training: Professional Claims (CMS 1500) and Beginner Billing Training: Institutional Claims (UB-04) available on the Provider Training web page under the Billing Training – Resources drop-down section.

For more training materials on navigating the Provider Web Portal, refer to the Provider Web Portal Quick Guides available on the Quick Guides web page.

Note: Trainings may end prior to 11:30 a.m. MT. Time has been allotted for questions at the end of each session.
<table>
<thead>
<tr>
<th>Sunday</th>
<th>Monday</th>
<th>Tuesday</th>
<th>Wednesday</th>
<th>Thursday</th>
<th>Friday</th>
<th>Saturday</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>1</td>
<td>2</td>
<td>3</td>
</tr>
<tr>
<td>4</td>
<td>5</td>
<td>6</td>
<td>7</td>
<td>8</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>9</td>
<td>10</td>
</tr>
<tr>
<td>11</td>
<td>12</td>
<td>13</td>
<td>14</td>
<td>15</td>
<td>16</td>
<td>17</td>
</tr>
<tr>
<td>18</td>
<td>19</td>
<td>20</td>
<td>21</td>
<td>22</td>
<td>23</td>
<td>24</td>
</tr>
<tr>
<td>25</td>
<td>26</td>
<td>27</td>
<td>28</td>
<td>29</td>
<td>30</td>
<td></td>
</tr>
</tbody>
</table>
May 2021

<table>
<thead>
<tr>
<th>Sunday</th>
<th>Monday</th>
<th>Tuesday</th>
<th>Wednesday</th>
<th>Thursday</th>
<th>Friday</th>
<th>Saturday</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>1</td>
</tr>
<tr>
<td>2</td>
<td>3</td>
<td>4</td>
<td>5</td>
<td>6</td>
<td>7</td>
<td>8</td>
</tr>
<tr>
<td>9</td>
<td>10</td>
<td>11</td>
<td>12</td>
<td>13</td>
<td>14</td>
<td>15</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>16</td>
<td>17</td>
<td>18</td>
<td>19</td>
<td>20</td>
<td>21</td>
<td>22</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>23/30</td>
<td>24/31</td>
<td>Memorial Day</td>
<td>25</td>
<td>26</td>
<td>27</td>
<td>28</td>
</tr>
</tbody>
</table>

**Beginner Billing Training:** Professional Claims (CMS 1500)
9:00 a.m. - 11:30 a.m.
MT

**Beginner Billing Training:** Institutional Claims (UB-04)
9:00 a.m. - 11:30 a.m.
MT

**Live Webinar Registration**

Register for a live webinar by clicking the title of the desired training session in the calendar above and completing the webinar registration form. An automated response will confirm the reservation. For questions or issues regarding webinar registration, email co.training@gainwelltechnologies.com with the subject line “Webinar Help.” Include a description of the issue being experienced, name and contact information (email address and phone number), and the name and date of the webinar(s) to be attended. Allow up to 2-3 business days to receive a response.
Upcoming Holidays

<table>
<thead>
<tr>
<th>Holiday</th>
<th>Closed Offices/Offices Open for Business</th>
</tr>
</thead>
<tbody>
<tr>
<td>Memorial Day</td>
<td>State Offices, DentaQuest, Gainwell Technologies and the ColoradoPAR Program will be closed. The receipt of warrants and EFTs may potentially be delayed due to the processing at the United State Postal Service or providers’ individual banks</td>
</tr>
<tr>
<td>Monday, May 31</td>
<td>--------------------------------------------------------------------------------------------------------</td>
</tr>
</tbody>
</table>

Gainwell Technologies Contacts

Provider Services Call Center
1-844-235-2387

Gainwell Technologies Mailing Address
P.O. Box 30
Denver, CO 80201